Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation
- PMID: 16829610
- PMCID: PMC1489574
- DOI: 10.1128/CVI.00139-06
Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation
Abstract
Cryptococcosis is an important complication of solid-organ transplantation, but the risk factors for disease are poorly understood. The goal of this study was to investigate whether specific or nonspecific serum immunoglobulin levels determined in samples obtained before and after solid-organ transplantation differed in patients who did or did not develop cryptococcosis after transplantation. We analyzed pretransplantation sera from 25 subjects, 15 who subsequently developed cryptococcosis and 10 who did not, and posttransplantation sera from 24 subjects, 13 who developed cryptococcosis and 11 who did not. All subjects received a tacrolimus-based immunosuppressive regimen. Total immunoglobulin levels were measured by immunodiffusion, and Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM)-specific serum antibody levels were determined by enzyme-linked immunosorbent assays. The results showed that solid-organ transplantation had a significant effect on total immunoglobulin and GXM-reactive antibody levels. GXM-reactive antibody levels differed in subjects who did and did not develop cryptococcosis. In pretransplant serum samples, the levels of GXM-reactive immunoglobulin M (IgM) were significantly lower in subjects who developed cryptococcosis after transplantation than in those who did not. For posttransplant serum samples, the levels of GXM-reactive IgM and IgG were significantly higher among the subjects who developed cryptococcosis than among those who did not. These findings suggest that perturbations in the preexisting antibody or B-cell repertoire and/or related to treatment of rejection, transplantation, or immunosuppressive therapy could translate into an increased risk for transplant-associated cryptococcosis.
Figures





Similar articles
-
Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection.J Infect Dis. 1999 Sep;180(3):915-9. doi: 10.1086/314953. J Infect Dis. 1999. PMID: 10438394
-
Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.Vaccine. 2004 Sep 28;22(29-30):4062-8. doi: 10.1016/j.vaccine.2004.03.060. Vaccine. 2004. PMID: 15364457
-
Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.Clin Exp Immunol. 1995 Mar;99(3):425-32. doi: 10.1111/j.1365-2249.1995.tb05568.x. Clin Exp Immunol. 1995. PMID: 7882565 Free PMC article.
-
Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.Trends Microbiol. 2001 Sep;9(9):445-51. doi: 10.1016/s0966-842x(01)02134-5. Trends Microbiol. 2001. PMID: 11553457 Review.
-
Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection.Front Biosci. 1998 Feb 1;3:d136-51. doi: 10.2741/a270. Front Biosci. 1998. PMID: 9445465 Review.
Cited by
-
Antibody immunity and natural resistance to cryptococcosis.Curr Trop Med Rep. 2019 Jun;6(2):50-54. doi: 10.1007/s40475-019-00174-1. Epub 2019 Apr 4. Curr Trop Med Rep. 2019. PMID: 31134140 Free PMC article.
-
Cryptococcus escapes host immunity: What do we know?Front Cell Infect Microbiol. 2022 Oct 13;12:1041036. doi: 10.3389/fcimb.2022.1041036. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36310879 Free PMC article. Review.
-
Antibody responses to Cryptococcus neoformans in Indian patients with cryptococcosis.Med Mycol. 2008 Aug;46(5):457-63. doi: 10.1080/13693780801961345. Epub 2008 Mar 10. Med Mycol. 2008. PMID: 18608912 Free PMC article.
-
The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans.J Immunol. 2010 May 15;184(10):5755-67. doi: 10.4049/jimmunol.0901638. Epub 2010 Apr 19. J Immunol. 2010. PMID: 20404271 Free PMC article.
-
Cryptococcus neoformans-Specific and Non-Cryptococcus neoformans-Specific Antibody Profiles in Organ Transplant Recipients With and Without Cryptococcosis.Open Forum Infect Dis. 2022 Apr 20;9(7):ofac211. doi: 10.1093/ofid/ofac211. eCollection 2022 Jul. Open Forum Infect Dis. 2022. PMID: 35794949 Free PMC article.
References
-
- Abadi, J., J. Friedman, R. Jefferis, R. A. Mageed, and L. Pirofski. 1998. Human antibodies elicited by a pneumococcal vaccine express idiotypic determinants indicative of VH3 gene segment usage. J. Infect. Dis. 178:707-716. - PubMed
-
- Agematsu, K., T. Futatani, S. Hokibara, N. Kobayashi, M. Takamoto, S. Tsukada, H. Suzuki, S. Koyasu, T. Miyawaki, K. Sugane, A. Komiyama, and H. D. Ochs. 2002. Absence of memory B cells in patients with common variable immunodeficiency. Clin. Immunol. 103:34-42. - PubMed
-
- Avanzini, M. A., F. Locatelli, S. C. Dos, R. Maccario, E. Lenta, M. Oliveri, S. Giebel, P. De Stefano, F. Rossi, G. Giorgiani, G. Amendola, S. Telli, and M. Marconi. 2005. B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells. Exp. Hematol. 33:480-486. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical